Bio-Rad Laboratories, Inc. (BIO) — Fair Value Analysis

Base-case fair value (P50): $287.00 · Current price: $285.41 · Verdict: Fairly Valued

The Verdict on BIO

Based on Monte Carlo simulations, BIO RAD LABORATORIES INC CLASS A (BIO) is currently Fairly Valued. Our analysis indicates a median fair value (P50) of $287.00, which is tightly aligned with the stock's current price of $285.41. This represents a modest potential upside of +0.6% from the current trading levels, suggesting the market has largely priced in the company's current fundamentals and future prospects as modeled. The Monte Carlo approach evaluates thousands of forward scenarios, converging on a robust valuation view for BIO, despite its weak quality tier.

How BIO stacks up against peers

BIO's quality tier is assessed as weak in relation to its sector, reflecting operational and financial health metrics that trail some counterparts. Despite this relative weakness, our simulations suggest the market has accurately discounted this factor, leading to the Fairly Valued verdict. The close proximity of BIO's $285.41 to its $287.00 fair value implies that even with a weak quality standing, its present valuation isn't punitive, nor does it present a significant discount for investors seeking alpha based purely on valuation. Investors should consider how the weak quality tier might influence future performance and risk.

What this means for investors

For investors tracking BIO, the minimal +0.6% to the median fair value of $287.00 from the $285.41 point suggests that the immediate upside is limited, according to our Monte Carlo models. While the Fairly Valued assessment means BIO is not overtly expensive, its weak quality tier warrants careful consideration. A deeper dive into the full range of outcomes, including downside and bull case scenarios, becomes critical here. FairCurve provides this detailed perspective, helping investors understand the full distribution of potential fair values. Sign up for FairCurve to see the complete bear and bull distribution and track BIO's fair value as new fundamentals are released.